

LncRNA TINCR attenuates cardiac hypertrophy by epig

Oncotarget

8, 47565-47573

DOI: [10.18632/oncotarget.17735](https://doi.org/10.18632/oncotarget.17735)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Long non-coding RNA CHRF facilitates cardiac hypertrophy through regulating Akt3 via miR-93. <i>Cardiovascular Pathology</i> , 2018, 35, 29-36.	0.7	41
2	Long non-coding RNAs in the failing heart and vasculature. <i>Non-coding RNA Research</i> , 2018, 3, 118-130.	2.4	55
4	Inhibition of HSF2 SUMOylation via MEL18 upregulates IGF-IIR and leads to hypertension-induced cardiac hypertrophy. <i>International Journal of Cardiology</i> , 2018, 257, 283-290.	0.8	29
5	LncRNA TINCR is downregulated in diabetic cardiomyopathy and relates to cardiomyocyte apoptosis. <i>Scandinavian Cardiovascular Journal</i> , 2018, 52, 335-339.	0.4	32
6	Progress of Genomics in Hypertensionâ€œCardiac Hypertrophy. <i>Translational Bioinformatics</i> , 2018, , 179-217.	0.0	0
8	Noncoding RNAs in Cardiac Hypertrophy. <i>Journal of Cardiovascular Translational Research</i> , 2018, 11, 439-449.	1.1	42
9	EZH2 Inhibition Ameliorates Transverse Aortic Constriction-Induced Pulmonary Arterial Hypertension in Mice. <i>Canadian Respiratory Journal</i> , 2018, 2018, 1-8.	0.8	18
10	Inhibition of lncRNA PFRL prevents pulmonary fibrosis by disrupting the miR-26a/smad2 loop. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2018, 315, L563-L575.	1.3	32
11	Non-coding RNA-linked epigenetic regulation in cardiac hypertrophy. <i>International Journal of Biological Sciences</i> , 2018, 14, 1133-1141.	2.6	29
12	3D genomic regulation of lncRNA and Xist in X chromosome. <i>Seminars in Cell and Developmental Biology</i> , 2019, 90, 174-180.	2.3	15
13	Exploring the Continuum of Hypertrophic Cardiomyopathyâ€œFrom DNA to Clinical Expression. <i>Medicina (Lithuania)</i> , 2019, 55, 299.	0.8	20
14	Long non-coding RNAs as new regulators of cardiac electrophysiology and arrhythmias: Molecular mechanisms, therapeutic implications and challenges. , 2019, 203, 107389.		38
15	The lncRNA <i>Hand2os1</i> / <i>Uph</i> locus orchestrates heart development through regulation of precise expression of <i>Hand2</i> . <i>Development (Cambridge)</i> , 2019, 146, .	1.2	48
16	Doxorubicin induces cardiomyocyte pyroptosis via the TINCR-mediated posttranscriptional stabilization of NLR family pyrin domain containing 3. <i>Journal of Molecular and Cellular Cardiology</i> , 2019, 136, 15-26.	0.9	75
17	STAT3-induced upregulation of lncRNA MEG3 regulates the growth of cardiac hypertrophy through miR-361-5p/HDAC9 axis. <i>Scientific Reports</i> , 2019, 9, 460.	1.6	49
18	Sp1-induced lncRNA CTBP1-AS2 is a novel regulator in cardiomyocyte hypertrophy by interacting with FUS to stabilize TLR4. <i>Cardiovascular Pathology</i> , 2019, 42, 21-29.	0.7	30
19	Silencing of Long Noncoding RNA Nespas Aggravates Microglial Cell Death and Neuroinflammation in Ischemic Stroke. <i>Stroke</i> , 2019, 50, 1850-1858.	1.0	56
20	LncRNA TUG1 contributes to cardiac hypertrophy via regulating miR-29b-3p. <i>In Vitro Cellular and Developmental Biology - Animal</i> , 2019, 55, 482-490.	0.7	26

#	ARTICLE	IF	CITATIONS
21	Long non-coding RNA small nucleolar RNA host gene 7 facilitates cardiac hypertrophy via stabilization of SDA1 domain containing 1 mRNA. <i>Journal of Cellular Biochemistry</i> , 2019, 120, 15089-15097.	1.2	14
22	SP1-SYNE1-AS1-miR-525-5p feedback loop regulates Ang-II-induced cardiac hypertrophy. <i>Journal of Cellular Physiology</i> , 2019, 234, 14319-14329.	2.0	21
23	LincRNA TINCR facilitates excessive proliferation and inflammation in post-burn skin fibroblasts by directly binding with SND1 protein and inducing SND1-mediated TGF- β 1 expression. <i>Biochemical and Biophysical Research Communications</i> , 2019, 509, 903-910.	1.0	8
24	Long noncoding RNA MAGI1-T1 regulates cardiac hypertrophy by modulating miR-302e/DKK1/Wnt/beta-catenin signaling pathway. <i>Journal of Cellular Physiology</i> , 2020, 235, 245-253.	2.0	25
25	Long non-coding RNAs in cardiac hypertrophy. <i>Heart Failure Reviews</i> , 2020, 25, 1037-1045.	1.7	10
26	LncRNAs in cardiac hypertrophy: From basic science to clinical application. <i>Journal of Cellular and Molecular Medicine</i> , 2020, 24, 11638-11645.	1.6	20
27	Knockdown of KCNQ1OT1 attenuates cardiac hypertrophy through modulation of the miR-2054/AKT3 axis. <i>Journal of Thoracic Disease</i> , 2020, 12, 4771-4780.	0.6	7
28	Morphine post-conditioning-induced up-regulation of lncRNA TINCR protects cardiomyocytes from ischemia-reperfusion injury via inhibiting degradation and ubiquitination of FGF1. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2020, 113, 859-869.	0.2	6
29	LncRNA Tincr regulates PKC δ expression in a miR-31-5p-dependent manner in cardiomyocyte hypertrophy. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2020, 393, 2495-2506.	1.4	9
30	Epigenetic regulation and mechanobiology. <i>Biophysics Reports</i> , 2020, 6, 33-48.	0.2	13
31	An Overview of the Role of Calcium/Calmodulin-Dependent Protein Kinase in Cardiorenal Syndrome. <i>Frontiers in Physiology</i> , 2020, 11, 735.	1.3	30
32	Regulatory RNAs in Heart Failure. <i>Circulation</i> , 2020, 141, 313-328.	1.6	133
33	Role of the Epigenome in Heart Failure. <i>Physiological Reviews</i> , 2020, 100, 1753-1777.	18.1	57
34	Long noncoding RNAs: Potential therapeutic targets in cardiocerebrovascular diseases. , 2021, 221, 107744.		22
35	Non-coding RNAs in Cardiomyopathy and Heart Failure. , 2021, , 119-147.		0
36	Role of long non-coding RNAs in adipogenesis: State of the art and implications in obesity and obesity-associated diseases. <i>Obesity Reviews</i> , 2021, 22, e13203.	3.1	26
37	LncRNAs in Cardiomyocyte Maturation: New Window for Cardiac Regenerative Medicine. <i>Non-coding RNA</i> , 2021, 7, 20.	1.3	6
38	NLRP3 Inflammasome: A Promising Therapeutic Target for Drug-Induced Toxicity. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 634607.	1.8	18

#	ARTICLE	IF	CITATIONS
39	Epigenetic Regulation of Autophagy in Cardiovascular Pathobiology. <i>International Journal of Molecular Sciences</i> , 2021, 22, 6544.	1.8	8
40	Reconnoitering the Role of Long-Noncoding RNAs in Hypertrophic Cardiomyopathy: A Descriptive Review. <i>International Journal of Molecular Sciences</i> , 2021, 22, 9378.	1.8	7
41	Role of acetylation in doxorubicin-induced cardiotoxicity. <i>Redox Biology</i> , 2021, 46, 102089.	3.9	59
42	Function of histone methylation and acetylation modifiers in cardiac hypertrophy. <i>Journal of Molecular and Cellular Cardiology</i> , 2021, 159, 120-129.	0.9	22
43	Epigenetic mechanisms underlying the benefits of flavonoids in cardiovascular health and diseases: are long non-coding RNAs rising stars?. <i>Critical Reviews in Food Science and Nutrition</i> , 2022, 62, 3855-3872.	5.4	15
44	Long Non-Coding RNAs (lncRNAs) in Cardiovascular Disease Complication of Type 2 Diabetes. <i>Diagnostics</i> , 2021, 11, 145.	1.3	16
45	Non-coding RNAs and Pathological Cardiac Hypertrophy. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1229, 231-245.	0.8	7
46	Non-coding RNAs as Epigenetic Gene Regulators in Cardiovascular Diseases. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1229, 133-148.	0.8	14
47	Long Noncoding RNA FTX Reduces Hypertrophy of Neonatal Mouse Cardiac Myocytes and Regulates the PTEN/PI3K/Akt Signaling Pathway by Sponging MicroRNA-22. <i>Medical Science Monitor</i> , 2019, 25, 9609-9617.	0.5	13
48	lncRNA ZEB2-AS1 stimulates cardiac hypertrophy by downregulating PTEN. <i>Experimental and Therapeutic Medicine</i> , 2020, 20, 1-1.	0.8	6
50	lncRNA TINCR improves cardiac hypertrophy by regulating the miR-211-3p-VEGFB-SDF-1 β -CXCR4 pathway. <i>Laboratory Investigation</i> , 2022, 102, 253-262.	1.7	2
51	Long Non-Coding RNAs in Cardiac Hypertrophy. <i>Frontiers in Molecular Medicine</i> , 2022, 2, .	0.6	0
52	Non-Coding RNAs in the Therapeutic Landscape of Pathological Cardiac Hypertrophy. <i>Cells</i> , 2022, 11, 1805.	1.8	3
53	Association of the Genetic Variation in the Long Non-Coding RNA FENRR with the Risk of Developing Hypertrophic Cardiomyopathy. <i>Life</i> , 2022, 12, 818.	1.1	3
54	Downregulation of lncRNA MALAT1 Inhibits Angiotensin II-induced Hypertrophic Effects of Cardiomyocytes by Regulating SIRT4 via miR-93-5p. <i>International Heart Journal</i> , 2022, 63, 602-611.	0.5	5
55	lncRNA NBR2 attenuates angiotensin II-induced myocardial hypertrophy through repressing ER stress via activating LKB1/AMPK/Sirt1 pathway. <i>Bioengineered</i> , 2022, 13, 13667-13679.	1.4	7
56	LincRNA RMRP regulates phenylephrine-induced cardiomyocyte hypertrophy via targeting miR-1. <i>Journal of Cardiovascular Pharmacology</i> , 2022, Publish Ahead of Print, .	0.8	3
57	lncRNA Gm43843 Promotes Cardiac Hypertrophy via miR-153-3p/Cacna1c Axis. <i>Evidence-based Complementary and Alternative Medicine</i> , 2022, 2022, 1-13.	0.5	1

#	ARTICLE	IF	CITATIONS
58	Illuminating the Molecular Intricacies of Exosomes and ncRNAs in Cardiovascular Diseases: Prospective Therapeutic and Biomarker Potential. <i>Cells</i> , 2022, 11, 3664.	1.8	2
59	Circulatory long noncoding RNAs (circulatory-LNC-RNAs) as novel biomarkers and therapeutic targets in cardiovascular diseases: Implications for cardiovascular diseases complications. <i>International Journal of Biological Macromolecules</i> , 2023, 225, 1049-1071.	3.6	3
60	Comparative Analysis of Non-Coding RNA Transcriptomics in Heart Failure. <i>Biomedicines</i> , 2022, 10, 3076.	1.4	5
61	Epigenetic mechanisms in cardiovascular diseases. , 2023, , 393-421.		0
62	SLC26A4-AS1 Agrava a Hipertrofia Card�aca Induzida por AngII Aumentando a Express�o de SLC26A4. <i>Arquivos Brasileiros De Cardiologia</i> , 2023, 120, .	0.3	1
64	The potential roles of lncRNA TINCR in triple negative breast cancer. <i>Molecular Biology Reports</i> , 0, , .	1.0	0